ArriVent to present preclinical data on firmonertinib and ARR-002 at AACR 2026

ArriVent BioPharma, Inc.

Firmonertinib preclinical data shows high potency and brain penetrance; supports ongoing Phase 3 in EGFR ex20ins NSCLC.
ARR-002 (MUC16/NaPi2b ADC) shows superior in vivo efficacy vs single-target ADCs in OVCAR-3 xenograft model.
ARR-002 demonstrates favorable tolerability in cynomolgus monkeys with reversible hematologic findings.
ARR-002 also selected for oral presentation at AACR Clinical Research Mini Symposium by Aarvik.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.